Info@ThinkPinkRocks.com

Lilly, Sarah Cannon Research Institute partner to co‑develop investigational oncology compound

Eli Lilly and Company and Sarah Cannon Research Institute today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management

Read the article:
Lilly, Sarah Cannon Research Institute partner to co‑develop investigational oncology compound

Share

Leave a Reply